[HTML][HTML] T cell responses to SARS-CoV-2

A Sette, J Sidney, S Crotty - Annual review of immunology, 2023 - annualreviews.org
A large body of evidence generated in the last two and a half years addresses the roles of T
cells in SARS-CoV-2 infection and following vaccination. Infection or vaccination induces …

[HTML][HTML] Vaccination and immunotherapies in neuroimmunological diseases

A Winkelmann, M Loebermann, M Barnett… - Nature Reviews …, 2022 - nature.com
Neuroimmunological diseases and their treatment compromise the immune system, thereby
increasing the risk of infections and serious illness. Consequently, vaccinations to protect …

[HTML][HTML] A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection

DG Augusto, LD Murdolo, DSM Chatzileontiadou… - Nature, 2023 - nature.com
Studies have demonstrated that at least 20% of individuals infected with SARS-CoV-2
remain asymptomatic,,–. Although most global efforts have focused on severe illness in …

Immune responses to SARS‐CoV‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis

GY Gombolay, M Dutt, W Tyor - Annals of Clinical and …, 2022 - Wiley Online Library
Abstract Introduction Responses to SARS‐CoV‐2 vaccination in patients with MS (pwMS)
varies by disease‐modifying therapies (DMTs). We perform a meta‐analysis and systematic …

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy

AT Reder, O Stuve, SK Tankou… - Multiple Sclerosis …, 2023 - journals.sagepub.com
Background: Multiple sclerosis (MS) is a neurological disorder marked by accumulating
immune-mediated damage to the central nervous system. The dysregulated immune system …

[HTML][HTML] S1PR1 inhibition induces proapoptotic signaling in T cells and limits humoral responses within lymph nodes

D Dixit, VM Hallisey, EYS Zhu… - The Journal of …, 2024 - Am Soc Clin Investig
Effective immunity requires a large, diverse naive T cell repertoire circulating among
lymphoid organs in search of antigen. Sphingosine 1-phosphate (S1P) and its receptor …

Cellular and humoral immunity to SARS‐CoV‐2 infection in multiple sclerosis patients on ocrelizumab and other disease‐modifying therapies: a multi‐ethnic …

I Kister, Y Patskovsky, R Curtin, J Pei… - Annals of …, 2022 - Wiley Online Library
Objective The objective of this study was to determine the impact of multiple sclerosis (MS)
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity …

[HTML][HTML] Inducing broad-based immunity against viruses with pandemic potential

A Sette, EO Saphire - Immunity, 2022 - cell.com
The brutal toll of another viral pandemic can be blunted by investing now in research that
uncovers mechanisms of broad-based immunity so we may have vaccines and therapeutics …

[HTML][HTML] Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1 …

JJ Sabatino Jr, K Mittl, W Rowles, CR Zamecnik… - Multiple Sclerosis and …, 2023 - Elsevier
Background Adequate response to the SARS-CoV-2 vaccine represents an important
treatment goal in caring for patients with multiple sclerosis (MS) during the ongoing COVID …

[HTML][HTML] Humoral and cellular response to spike of delta SARS-CoV-2 variant in vaccinated patients with multiple sclerosis

L Petrone, C Tortorella, A Aiello, C Farroni… - Frontiers in …, 2022 - frontiersin.org
Objectives We assessed vaccination-induced antibody and cellular response against spike
from the ancestral strain and from the Delta Severe Acute Respiratory Syndrome …